DC-based immunotherapyReduced efficacy in obese renal carcinoma model, associated with increased regulatory DCs and decreased CD8+ T cells.Potential improved response on combining DC-based immunotherapy with obesity interventions. Here, CD8A is linked to renal carcinoma.